Human-Validated Disease Targeting Framework
Start with causal human biology, then choose the best therapeutic tool
- Difficulty
- Advanced
- Time to result
- ~months to results
- Steps
- 6
- Confidence
- 90%
The framework begins by selecting a serious disease where patients face substantial unmet need and where enough research exists to form a credible biological hypothesis. Researchers then identify the causal human biology and look for targets supported by evidence from people rather than relying only on laboratory models. Only after defining and validating the target do they compare possible interventions. The team remains modality-agnostic, considering whichever tool can best address the mechanism instead of forcing the problem into a preferred technology. The intended output is a therapeutic approach that acts on an underlying disease driver and has the potential to transform outcomes. This ordering reduces technology-led bias while connecting disease selection, target validation, and intervention design into one repeatable research process.
Origin
Extracted from Masters in Business, in a sponsored episode about Vertex Pharmaceuticals' approach to IgA nephropathy research.
Core principles
- 01Prioritize serious diseases with substantial unmet need
- 02Build on credible human biology and validated targets
- 03Aim at the underlying disease rather than symptoms alone
- 04Choose the therapeutic modality only after understanding the biology
- 05Remain tool-agnostic throughout solution design
How to run it
- 1
Select a consequential disease
Identify a serious condition with substantial unmet patient need. Confirm that a meaningful improvement would materially change patients' lives.
Pro tip Favor diseases where the underlying mechanism may be addressable rather than merely managed.
Watch out A large patient population alone does not establish a tractable biological opportunity.
- 2
Map the causal human biology
Determine the biological chain that produces injury or disease progression. Distinguish upstream drivers from downstream symptoms and damage.
Pro tip Express the mechanism as a causal sequence from driver to measurable clinical effect.
Watch out Do not mistake correlation with a disease marker for evidence of causation.
- 3
Validate targets in humans
Prioritize targets supported by human observations, such as disease-associated protein levels, genetics, pathology, or clinical measurements. Assess whether the evidence connects the target to both mechanism and severity.
Pro tip Use multiple independent forms of human evidence when possible.
Watch out Evidence from experimental models may not translate into human benefit.
- 4
Assess technical tractability
Establish whether an existing technology can address the target or whether a suitable capability can realistically be developed. Consider delivery, selectivity, safety, and measurable biological response.
Pro tip Define the technical requirements before comparing named modalities.
Watch out Do not advance an attractive target without a credible way to reach or modulate it.
- 5
Choose the right tool
Compare therapeutic approaches only after clarifying the biology and target requirements. Select the modality that best fits the mechanism without privileging a familiar platform.
Pro tip Include a deliberate challenge session in which the team argues for alternative modalities.
Watch out Platform loyalty can force the disease into the wrong technical solution.
- 6
Test for transformative potential
Evaluate whether the proposed approach could alter the underlying disease and produce clinically meaningful outcomes. Define biomarkers and patient outcomes that would demonstrate success.
Pro tip Connect each biological measurement to an outcome patients would recognize as valuable.
Watch out A measurable biological effect is insufficient if it does not improve or preserve patient health.
In the wild
Researchers map uncontrolled B-cell activity to harmful antibody production and observe that BAFF and APRIL are both elevated in people with IgA nephropathy. Because each protein contributes at a different stage of the B-cell life cycle, the team evaluates an approach that addresses both drivers rather than choosing a technology first or targeting only one pathway.
→ The resulting research hypothesis aims to restore immune balance, reduce blood and protein leakage into urine, and stabilize kidney function.
A biotechnology team considering a new lung-fibrosis program first verifies a serious unmet need, maps the human pathway associated with progressive scarring, and validates an upstream target using patient tissue and outcome data. It then compares antibodies, small molecules, and gene-silencing approaches against explicit delivery and safety requirements.
→ The team selects a modality based on biological fit and abandons an initially favored platform that cannot reliably reach the target tissue.
Common mistakes
Choosing the technology first
Starting with a favored platform encourages researchers to reshape the biological problem around the tool instead of selecting the tool that fits the mechanism.
Treating association as validation
A biomarker that moves with disease severity may not drive the disease. Target validation should establish a credible causal role supported by human evidence.
Targeting only downstream damage
Reducing a symptom or late-stage consequence may leave the initiating mechanism intact and limit the possibility of transformative benefit.
Is it for you?
Best for
This is best for biotechnology research teams selecting diseases, targets, and therapeutic modalities under scientific uncertainty.
Not ideal for
It is not ideal for conditions whose causal biology and human-validating evidence remain too weak to support target selection.
From the transcript
“There's a long history of research to build on there's new technology available or Vertex thinks they can develop it. There's a large unmet need,…”
“Now, we focus on cause of human biology and on human validated targets, and then we ask the question what's the right approach to take,…”
“We'll use whatever is the right tool in the toolbox if you like, to address their biology and then to come up with a transformative…”
From the episode
Targeting IgA Nephropathy (Sponsored Content)